Morphology of regional lymph nodes in experimental prostate carcinogenesis
DOI: 10.32364/2587-6821-2022-6-4-171-176
V.V. Astashov1, A.A. Lomshakov2, T.A. Tsekhmistrenko1, O.F. Vykhristyuk1,3, M.V. Uloga1, I.Yu. Borodina1, A.O. Tolkachev4
1People’s Friendship University of Russia (RUDN University), Moscow, Russian Federation
2Polyclinic FNPR, Moscow, Russian Federation
3Pirogov Russian National Research Medical University, Moscow, Russian Federation
4P.A. Hertsen Moscow Oncology Research Institute — the branch of the National Medical Research Radiological Centre, Moscow, Russian Federation
Background: the migration of tumor cells into blood and lymphatic vessels is a key stage of the metastatic process in malignant neoplasms. Moreover, the presence of tumor cells in the lymph nodes is an indicator of cancer aggressiveness, and the histopathological characteristics of the lymph nodes are one of the important parameters for the treatment prognosis and patient survival.
Aim: to evaluate changes in the lymph nodes of mice during experimental carcinogenesis in the prostate gland.
Material and Methods: the study was conducted on CBA inbred 3-month-old male mice (n=30). To create a model of malignant tumor growth in the prostate gland, a diluted cell strain of transplantable Ehrlich ascites carcinoma was inoculated into the prostate parenchyma. A model of prostate carcinogenesis was created in 18 days by transplanting Ehrlich ascites carcinoma into prostate tissue in mice (n=15; main group). The remaining 15 mice were in the control group. All manipulations with animals were carried out in compliance with the basic ethical principles. After the animals were removed from the experiment, a morphological analysis of the prostate and regional (pelvic) lymph nodes was performed. The area and cellular composition concerning the main structural and functional zones of the pelvic lymph nodes in both groups of animals were evaluated.
Results: this study showed that the cellular composition changed in the setting of prostate carcinogenesis in the pelvic lymph nodes. In the main group of animals, the number of immunoblasts significantly prevailed in the germinal center of secondary lymphoid nodules versus the control group (p<0,05). An increase in immunoblasts by almost 2 times in mice (experimental group) indicated the inhibition of humoral immunity in prostate carcinogenesis. Also, in the main group, the area of the cortical substance decreased by 14.5% and the area of the paracortex increased by 28.4% versus the control group (p<0,05).
Conclusion: the first metastases of prostate cancer appear in regional lymph nodes. On the 18th day of prostate carcinogenesis, the structure of regional lymph nodes undergoes changes: paracortical hyperplasia, a decrease in the area of medullary cords and medullary substance, a decrease in cerebral sinuses.
Keywords: prostate cancer, carcinogenesis, experiment, Ehrlich ascites carcinoma, lymphangiogenesis, lymph node, regional metastases.
For citation: Astashov V.V., Lomshakov A.A., Tsekhmistrenko T.A. et al. Morphology of regional lymph nodes in experimental prostate carcinogenesis. Russian Medical Inquiry. 2022;6(4):171–176 (in Russ.). DOI: 10.32364/2587-6821-2022-6-4-171-176.
About the authors:
Vadim V. Astashov — Dr. Sc. (Med.), Professor, Professor of the Department of Human Anatomy, Medical Institute of the Peoples’ Friendship University of Russia (RUDN University); 8 Miklukho-Maklay str., Moscow, 117198, Russian Federation; ORCID iD 0000-0003-2846-1944.
Andrey A. Lomshakov — C. Sc. (Med.), urologist of Polyclinic FNPR; 37 Leninsky Ave., Moscow, 119334, Russian Federation; ORCID iD 0000-0001-5831-5409.
Tatiana A. Tsekhmistrenko — Dr. Sc. (Bio.), Professor, Professor of the Department of Human Anatomy of the Peoples’ Friendship University of Russia (RUDN University); 8 Miklukho-Maklay str., Moscow, 117198, Russian Federation; ORCID iD 0000-0003-2130-9405.
Olga F. Vyhristyuk — Dr. Sc. (Med.), Professor of the Department of Evidence-based Medicine, Medical Institute of the Peoples’ Friendship University of Russia (RUDN University); 8 Miklukho-Maklay str., Moscow, 117198, Russian Federation; Professor of the Department of Pediatrics, Medical Faculty of Pirogov Russian National Research Medical University; 1 Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-0352-9642.
Mikhail V. Uloga — Assistant Professor of the Department of Human Anatomy, Medical Institute of the Peoples’ Friendship University of Russia (RUDN University); 8 Miklukho-Maklay str., Moscow, 117198, Russian Federation; ORCID iD 0000-0002-1274-8310.
Inna Yu. Borodina — Assistant Professor of the Department of Human Anatomy, Medical Institute of the Peoples’ Friendship University of Russia (RUDN University); 8 Miklukho-Maklay str., Moscow, 117198, Russian Federation; ORCID iD 0000-0002-8640-1379.
Alexander O. Tolkachev — Junior Fellow of the Department of Oncourology, P. A. Hertsen Moscow Oncology Research Institute — the branch of the National Medical Research Radiological Centre; 3, 2nd Botkinskiy pass., Moscow, 125284, Russian Federation; ORCID iD 0000-0002-8630-6072.
Contact information: Vadim V. Astashov, e-mail: vastashov3@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 28.01.2022.
Revised 22.02.2022.
Accepted 22.03.2022.
2. Kohaar I., Petrovics G., Srivastava S. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. Int J Mol Sci. 2019;20(8):1813. DOI: 10.3390/ijms20081813.
3. Kaprin A.D., Kostin A.A., Kulchenko N.G., Tolkachev A.O. Prostate cancer screening based on multivariant analysis. Bulletin of the Medical Institute "REAVIZ". Rehabilitation, Doctor and Health. 2014;4(16):38–42 (in Russ.).
4. Krasheninnikov A.A., Nyushko K.M., Vorobev N.V. et al. Adenosquamous cell cancer of the prostate: a clinical case. South Russian Journal of Cancer. 2020;1(1):60–68 (in Russ.). DOI: 10.37748/2687-0533-2020-1-1-5.
5. Ramalingam S., Ramamurthy V.P., Njar V.C.O. Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. J Steroid Biochem Mol Biol. 2017;166:16–27. DOI: 10.1016/j.jsbmb.2016.07.006.
6. Kostin A.A., Asratov A.T., Kulchenko N.G., Tolkachev A.O. Prediction of prostate cancer by the general discriminant analysis models. RUDN Journal of Medicine. 2015;3:67–74 (in Russ.).
7. Merriel S.W.D., Funston G., Hamilton W. Prostate Cancer in Primary Care. Adv Ther. 2018;35(9):1285–1294. DOI: 10.1007/s12325-018-0766-1.
8. Kulchenko N.G., Tolkachev A.O. Prostate cancer in the 21st century: a literature review. Medical Institute "REAVIZ". Rehabilitation, Doctor and Health. 2017;6(30):106–113 (in Russ.).
9. Aboian I.A., Fedotova E.N., Shevchenko A.N. et al. Current biomarkers of prostate cancer. Research and Practical Medicine Journal. 2021;8(4):96–108 (in Russ.). DOI: 10.17709/2410-1893-2021-8-4-10.
10. Kostin A.A., Kulchenko N.G., Tolkachev A.O. Forecasting the development of cancer of prostate. Multidisciplinary approach. Medical Institute "REAVIZ". Rehabilitation, Doctor and Health. 2017;1(25):60–67 (in Russ.).
11. Parker C., Castro E., Fizazi K. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–1134. DOI: 10.1016/j.annonc.2020.06.011.
12. Kostin A.A., Kulchenko N.G., Tolkachev A.O. Prostate cancer. Principles of early diagnosis. RUDN Journal of Medicine. 2016;4:68–76 (in Russ.)
13. Telang J.M., Lane B.R., Cher M.L. et al. Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature. BJU Int. 2017;120(4):464–467. DOI: 10.1111/bju.13862.
14. Nassar Z.D., Moon H., Duong T. et al. PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis. Oncotarget. 2013;4(10):1844–1855. DOI: 10.18632/oncotarget.1300.
15. Cai T., Nesi G., Tinacci G. Clinical importance of lymph node density in predicting outcome of prostate cancer patients. J Surg Res. 2011;167:267–272. DOI: 10.1016/j.jss.2009.05.004.
16. Wu P.Y., Lin Y.C., Huang Y.L. et al. Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer. Cancers. 2018;10(11):413. DOI: 10.3390/cancers10110413.
17. Gromov A.I., Builov V.M. Radiation diagnostics and therapy in urology. М.: GEOTAR-Media; 2011 (in Russ.).
18. Wong S.Y., Haack H., Crowley D. et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res. 2005;65(21):9789–9798. DOI: 10.1158/0008-5472.CAN-05-0901.
19. Chen J.J., Zhu Z.S., Zhu Y.Y., Shi H.Q. Applied anatomy of pelvic lymph nodes and its clinical significance for prostate cancer: a single-center cadaveric study. BMC Cancer. 2020;20(1):330. DOI: 10.1186/s12885-020-06833-1.
20. Zarzour J.G., Galgano S., McConathy J. et al. Lymph node imaging in initial staging of prostate cancer: An overview and update. World J Radiol. 2017;9(10):389–399. DOI: 10.4329/wjr.v9.i10.389.
21. Sprute K., Kramer V., Koerber S.A. et al. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. J Nucl Med. 2021;62(2):208–213. DOI: 10.2967/jnumed.120.246363.
22. Stachura J., Wachowska M., Kilarski W.W. et al. The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. Oncoimmunology. 2016;5:e1182278. DOI: 10.1080/2162402X.2016.1182278.
23. Oliveira-Ferrer L., Milde-Langosch K., Eylmann K. et al. Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma. Int J Mol Sci. 2020;21(2):602. DOI: 10.3390/ijms21020602.
24. Stromvall K., Lundholm M., Thysell E. et al. Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth. PLOS One. 2017;12(10):e0187086. DOI: 10.1371/journal.pone.0187086.
25. Qian C.N., Takahashi M., Kahnoski R.J., Teh B.T. Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model. J Urol. 2003;170(3):994–997. DOI: 10.1097/01.ju.0000080321.99119.df.
26. Datta K., Muders M., Zhang H.Y., Tindall D.J. Mechanism of lymph node metastasis in prostate cancer. Future Oncol. 2010;6(5):823–836. DOI: 10.2217/FON.10.33.
27. Boormans J.L., Wildhagen M.F., Bangma C.H. et al. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer. BJU Int. 2008;102(11):1589–1593. DOI: 10.1111/j.1464-410X.2008.07904.x.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
